Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $278000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 90.41% to $278000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $278000.0 through Sep 2025, up 90.41% year-over-year, with the annual reading at $135000.0 for FY2024, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $278000.0 at TScan Therapeutics, up from $113000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $278000.0 in Q3 2025, with the low at $12000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $118600.0, with a median of $97000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities crashed 87.63% in 2023, then skyrocketed 1116.67% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $97000.0 in 2021, then crashed by 49.48% to $49000.0 in 2022, then plummeted by 75.51% to $12000.0 in 2023, then skyrocketed by 1025.0% to $135000.0 in 2024, then surged by 105.93% to $278000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $278000.0, $113000.0, and $124000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.